The latest clinical trials have also found that the activation of NF‐κB in RA patients treated with β‐d‐mannuronic acid is significantly reduced, as well as the levels of IL‐6 and TNFα in serum, reflecting the prospect of this treatment.207. This evidence concerns the gene NFKB1 and rheumatoid arthritis.